Option Care Health (OPCH)
Market Price (12/30/2025): $32.195 | Market Cap: $5.2 BilSector: Health Care | Industry: Health Care Facilities
Option Care Health (OPCH)
Market Price (12/30/2025): $32.195Market Cap: $5.2 BilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Low stock price volatilityVol 12M is 33% | Weak multi-year price returns2Y Excs Rtn is -50%, 3Y Excs Rtn is -73% | Key risksOPCH key risks include [1] persistent margin pressure from reduced reimbursement rates by third-party payers and [2] an anticipated negative impact on 2025 gross profit due to a key supplier's pricing change on a specific therapy. |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Oncology Treatments, Show more. |
| Low stock price volatilityVol 12M is 33% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Oncology Treatments, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -50%, 3Y Excs Rtn is -73% |
| Key risksOPCH key risks include [1] persistent margin pressure from reduced reimbursement rates by third-party payers and [2] an anticipated negative impact on 2025 gross profit due to a key supplier's pricing change on a specific therapy. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
1. Strong Third Quarter 2025 Financial Results. Option Care Health reported a significant increase in its third-quarter 2025 financial performance, with net revenue rising by 12.2% year-over-year to $1.435 billion. The company also saw a 6.3% increase in gross profit to $272.9 million and a 9.8% rise in Adjusted diluted EPS to $0.45.
2. Positive Updated Full-Year 2025 Financial Guidance. Following its strong Q3 performance, Option Care Health updated its full-year 2025 financial guidance, projecting net revenue between $5.60 billion and $5.65 billion, Adjusted EPS from $1.68 to $1.72, and Adjusted EBITDA from $468 million to $473 million. This positive outlook suggests continued growth and financial health.
Show more
Stock Movement Drivers
Fundamental Drivers
The 16.9% change in OPCH stock from 9/29/2025 to 12/29/2025 was primarily driven by a 17.2% change in the company's P/E Multiple.| 9292025 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 27.54 | 32.19 | 16.88% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 5374.02 | 5530.49 | 2.91% |
| Net Income Margin (%) | 3.93% | 3.78% | -3.77% |
| P/E Multiple | 21.24 | 24.90 | 17.23% |
| Shares Outstanding (Mil) | 162.93 | 161.83 | 0.68% |
| Cumulative Contribution | 16.88% |
Market Drivers
9/29/2025 to 12/29/2025| Return | Correlation | |
|---|---|---|
| OPCH | 16.9% | |
| Market (SPY) | 3.6% | 21.7% |
| Sector (XLV) | 14.7% | 21.6% |
Fundamental Drivers
The -0.9% change in OPCH stock from 6/30/2025 to 12/29/2025 was primarily driven by a -8.2% change in the company's Net Income Margin (%).| 6302025 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 32.48 | 32.19 | -0.89% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 5185.12 | 5530.49 | 6.66% |
| Net Income Margin (%) | 4.12% | 3.78% | -8.24% |
| P/E Multiple | 25.14 | 24.90 | -0.96% |
| Shares Outstanding (Mil) | 165.46 | 161.83 | 2.19% |
| Cumulative Contribution | -0.94% |
Market Drivers
6/30/2025 to 12/29/2025| Return | Correlation | |
|---|---|---|
| OPCH | -0.9% | |
| Market (SPY) | 11.6% | 28.3% |
| Sector (XLV) | 16.1% | 30.9% |
Fundamental Drivers
The 40.9% change in OPCH stock from 12/29/2024 to 12/29/2025 was primarily driven by a 33.4% change in the company's P/E Multiple.| 12292024 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 22.85 | 32.19 | 40.88% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 4776.17 | 5530.49 | 15.79% |
| Net Income Margin (%) | 4.37% | 3.78% | -13.50% |
| P/E Multiple | 18.67 | 24.90 | 33.38% |
| Shares Outstanding (Mil) | 170.64 | 161.83 | 5.16% |
| Cumulative Contribution | 40.50% |
Market Drivers
12/29/2024 to 12/29/2025| Return | Correlation | |
|---|---|---|
| OPCH | 40.9% | |
| Market (SPY) | 16.6% | 19.6% |
| Sector (XLV) | 13.6% | 33.9% |
Fundamental Drivers
The 7.0% change in OPCH stock from 12/30/2022 to 12/29/2025 was primarily driven by a 43.8% change in the company's Total Revenues ($ Mil).| 12302022 | 12292025 | Change | |
|---|---|---|---|
| Stock Price ($) | 30.09 | 32.19 | 6.98% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3844.72 | 5530.49 | 43.85% |
| Net Income Margin (%) | 4.64% | 3.78% | -18.52% |
| P/E Multiple | 30.66 | 24.90 | -18.79% |
| Shares Outstanding (Mil) | 181.88 | 161.83 | 11.03% |
| Cumulative Contribution | 5.68% |
Market Drivers
12/30/2023 to 12/29/2025| Return | Correlation | |
|---|---|---|
| OPCH | -4.5% | |
| Market (SPY) | 47.9% | 21.5% |
| Sector (XLV) | 17.6% | 33.9% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OPCH Return | 5% | 82% | 6% | 12% | -31% | 40% | 118% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 151% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 114% |
Monthly Win Rates [3] | |||||||
| OPCH Win Rate | 42% | 58% | 50% | 67% | 42% | 50% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| OPCH Max Drawdown | -59% | 0% | -66% | -11% | -35% | -2% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/29/2025 (YTD)
How Low Can It Go
| Event | OPCH | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -65.6% | -25.4% |
| % Gain to Breakeven | 190.3% | 34.1% |
| Time to Breakeven | 60 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -65.9% | -33.9% |
| % Gain to Breakeven | 193.0% | 51.3% |
| Time to Breakeven | 307 days | 148 days |
| 2018 Correction | ||
| % Loss | -59.7% | -19.8% |
| % Gain to Breakeven | 148.4% | 24.7% |
| Time to Breakeven | 260 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -85.8% | -56.8% |
| % Gain to Breakeven | 603.7% | 131.3% |
| Time to Breakeven | 510 days | 1,480 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Option Care Health's stock fell -65.6% during the 2022 Inflation Shock from a high on 1/3/2022. A -65.6% loss requires a 190.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-3 brief analogies for Option Care Health (OPCH):
- Netflix for hospital-level infusion treatments: Option Care Health brings complex, specialized medical care (like IV infusions) directly to a patient's home, much like Netflix delivers entertainment, disrupting traditional methods.
- Amazon Pharmacy for complex IV treatments and nursing care at home: Similar to how Amazon Pharmacy delivers prescriptions, OPCH delivers and administers complex intravenous medications along with professional nursing care directly to patients' residences.
- Uber for highly specialized home infusion therapy: Option Care Health provides convenient access to professional, specialized medical services (infusion therapy) delivered directly to the patient's location, akin to Uber bringing transportation services to you.
AI Analysis | Feedback
- Infusion Therapy Services: Delivers complex intravenous medications and clinical care to patients in their homes or alternate sites for various acute and chronic conditions.
- Nutritional Support: Provides specialized parenteral and enteral nutrition solutions and services for patients with complex dietary needs.
- Care Coordination & Management: Offers comprehensive patient support, education, and clinical monitoring to ensure optimal treatment outcomes and continuity of care.
AI Analysis | Feedback
Option Care Health (OPCH) primarily sells its specialized infusion and alternate site care services to other companies, specifically third-party payers.
According to its most recent SEC filings (e.g., the 10-K for the fiscal year ended December 31, 2023), no individual third-party payer accounted for 10% or more of Option Care Health's consolidated net revenues in any of the past three fiscal years. Therefore, Option Care Health does not have a single "major customer" in the financial reporting sense of one entity comprising a significant portion of its revenue.
Instead, its revenue is diversified across a wide network of payer relationships. The categories of customer companies it serves include:
- Commercial Health Plans: These are private insurance companies that provide health coverage to individuals and employer groups. Option Care Health contracts with a broad range of these plans across the United States. Examples of prominent companies in this category that are likely among their diverse customer base include:
- UnitedHealth Group (UNH)
- Elevance Health (ELV)
- CVS Health (via Aetna) (CVS)
- The Cigna Group (CI)
- Humana (HUM)
- Managed Care Organizations (MCOs): These organizations manage healthcare services for their members, often including those enrolled in Medicare Advantage and state Medicaid managed care programs. Many of the large commercial health plans listed above also operate significant MCO segments.
- Government Healthcare Programs: While not "companies" in the traditional sense, federal and state government programs such as Medicare and Medicaid are significant sources of payment for Option Care Health's services, often administered through contracted managed care organizations.
AI Analysis | Feedback
- McKesson Corporation (MCK)
- Cencora, Inc. (COR)
- Cardinal Health, Inc. (CAH)
AI Analysis | Feedback
John C. Rademacher, President & Chief Executive Officer
Mr. Rademacher possesses nearly two decades of experience in the healthcare industry, successfully deploying technology solutions and expanding professional services capabilities. He joined Option Care in 2015 as Chief Operating Officer and was named CEO of Option Care in January 2018, after serving as interim CEO since August 2017. Mr. Rademacher held various executive-level positions at leading healthcare companies, including President and General Manager for both the Ambulatory Care Division and the Nuclear and Pharmacy Services divisions at Cardinal Health. He also served as President of CareAllies and Chief Operating Officer for the CIGNA Behavioral Health business at Cigna Corporation.
Meenal Sethna, Executive Vice President & Chief Financial Officer
Ms. Sethna was appointed Executive Vice President and Chief Financial Officer, effective October 1, 2025. She is a seasoned public company CFO and business executive with over 30 years of broad experience across multiple industries. Ms. Sethna most recently served as Executive Vice President and Chief Financial Officer of Littelfuse, Inc., a publicly traded industrial technology company. Her responsibilities at Littelfuse included finance and accounting, tax and treasury, investor relations, digital and information technology, and supply chain operations. Prior to Littelfuse, she served as Vice President and Corporate Controller at Illinois Tool Works and held various roles at Motorola Inc. and Baxter International. Ms. Sethna has served on the Board of Directors of SPX Technologies, a publicly traded diversified, global supplier of highly engineered products and technologies, since 2019.
Luke Whitworth, Chief Operating Officer
Mr. Whitworth brings broad healthcare and leadership experience to Option Care Health. Prior to joining the company, he spent nearly fifteen years at Cardinal Health with a proven track record of accomplishment across Finance, Mergers and Acquisitions, Integration, Sales, and General Management. He served as the finance executive to build a multi-billion dollar post-acute business across distribution, services, and technology.
Mike Bavaro, Chief Human Resources Officer and Chief Diversity Officer
Mr. Bavaro serves Option Care Health with over 20 years of human resource leadership experience. Before joining Option Care Health in 2016, he served as divisional Vice President at Blue Cross Blue Shield of IL, TX, NM, MT & OK, a health insurance company. In this role, he was responsible for talent acquisition and workforce strategies and served as the interim Diversity and Inclusion Officer. He also held senior HR roles at Career Education Corporation and United Airlines.
Brett Michalak, Chief Information Officer
As CIO of Option Care Health, Mr. Michalak is responsible for all aspects of information technology, ensuring alignment of technology initiatives and operations with the Company's business goals and objectives. Prior to joining Option Care, Mr. Michalak was the CIO for Tickets.com, a privately held subsidiary of Major League Baseball Advanced Media, LP. In this role, he led the creation of the Provenue® software platform and was responsible for product development and technology organizations.
AI Analysis | Feedback
The key risks to Option Care Health (OPCH) are primarily centered around pricing pressures, pharmaceutical supply, and the competitive landscape of the healthcare industry.
- Pricing Pressures and Reimbursement Risks from Third-Party Payers: Option Care Health faces significant pressure from third-party payers, including managed care organizations, to contain or reduce healthcare costs. This competition and payer influence can lead to reduced reimbursement rates for home infusion and specialty pharmacy services, directly impacting the company's gross margins and net income. There is a "looming risk of payer reimbursement pressure" and "chronic therapy margin pressures" that could affect profitability.
- Changes in the Pharmaceutical Industry and Supply Chain: The company is exposed to risks related to the pharmaceutical industry, particularly concerning drug and supply shortages. Option Care Health relies on a limited number of suppliers for a significant portion of its pharmaceutical and medical supply purchases. A reduction in the supply of, or changes in the market for, compatible pharmaceuticals, as well as changes in FDA approval processes or drug recalls, could materially and adversely affect Option Care Health's financial condition and results of operations. The company anticipates a negative impact on gross profit in 2025 due to a manufacturer's intention to reduce the spread at which a certain therapy is procured.
- Highly Competitive Environment and Need for Adaptation: Option Care Health operates in a highly competitive and fragmented market. The company's services are sometimes described as "commodity-like," leading to low margins and intense competition that drives prices lower. Failure to develop new services or adapt to evolving changes and trends within the healthcare industry could adversely affect its business.
AI Analysis | Feedback
The clear emerging threat for Option Care Health (OPCH) is the ongoing trend in pharmaceutical development towards the reformulation of complex injectable and infusible drugs into patient-friendly, self-administrable forms, primarily subcutaneous injections or oral medications.
Many biologics, specialty drugs, and immunotherapies that traditionally required intravenous administration by a healthcare professional are increasingly being developed and approved in forms that allow patients or their caregivers to self-administer the medication at home. Examples include the development of subcutaneous versions of drugs initially available only intravenously.
This shift directly reduces the demand for professional home infusion services provided by companies like OPCH for the specific drugs that transition to self-administration. As more high-volume and high-margin therapies become available in these alternative forms, it poses a direct and significant threat to OPCH's service revenue and overall business model, as the core need for their service for those particular drugs diminishes.
AI Analysis | Feedback
Option Care Health (OPCH) operates primarily in the U.S. home and alternate site infusion services market, providing a range of therapies for acute and chronic conditions. These services include anti-infectives, nutrition support, immunoglobulin therapy, heart failure, bleeding disorders, chronic inflammatory disorders, neurological disorders, and women's health.
The addressable market sizes for Option Care Health's main products and services in the U.S. are as follows:
- The U.S. home infusion market is estimated to be between $17 billion and $18 billion.
- The total U.S. infusion market, which encompasses inpatient, physician outpatient offices, skilled nursing facilities, and home infusion, is approximately $100 billion.
AI Analysis | Feedback
Option Care Health (OPCH) is anticipated to drive future revenue growth over the next two to three years through several key strategies:
- Expansion of Home and Alternate Site Infusion Services: The company is strategically positioned to benefit from the increasing demand for home-based healthcare, expanding its services to meet this need. This shift towards convenient, cost-effective alternatives to traditional inpatient care is a significant growth trend in the healthcare industry.
- Growth in Specialty Pharmacy and Rare/Orphan Therapies: Option Care Health has demonstrated strong performance in its rare and orphan portfolios, along with continued growth in established therapeutic categories. These areas are expected to contribute to ongoing double-digit revenue growth.
- Strategic Acquisitions: Management has emphasized a continued focus on targeted "tuck-in" acquisitions and successful integration of prior deals to drive long-term earnings. This approach allows the company to expand its reach and capabilities.
- Expansion of Ambulatory Infusion Suites (AIS) and Advanced Practitioner Models: Option Care Health is actively increasing its penetration of infusion suites, which has doubled since the strategy's inception, with chronic patients being the primary users. The advanced practitioner model also enables the company to serve a broader and more complex patient population, thereby expanding its portfolio.
- Enhanced Partnerships: The company focuses on expanding relationships with managed care organizations, patient referral sources, and pharmaceutical manufacturers. These partnerships are crucial for broadening patient access, enhancing distribution channels, and supporting the launch of new products.
AI Analysis | Feedback
Share Repurchases
- Option Care Health increased its share repurchase program authorization from $250 million to $500 million in December 2023, with no specified expiration date.
- The company completed its previous $90 million buyback in Q4 2024 and subsequently announced a new $500 million stock repurchase program in January 2025.
- In the third quarter of 2025, Option Care Health completed a buyback of 6.76 million shares for $212.51 million, retiring over 4% of outstanding shares under its ongoing repurchase program. A $106 million break fee from a called-off merger with Amedisys was also used to repurchase stock in May 2024.
Share Issuance
- In March 2021, Option Care Health announced the pricing of a secondary offering of 12,000,000 shares of common stock.
Inbound Investments
- No specific large inbound investments from third-party strategic partners or private equity firms were identified within the last 3-5 years.
Outbound Investments
- In December 2022, Option Care Health divested its respiratory therapy assets in the U.S. Northeast, which generated $18.4 million.
- The company made small "tuck-in" acquisitions in late 2024, specifically in Texas and Florida, which contributed approximately $25 million to sales in Q2 2025.
- Option Care Health has a history of acquiring companies at reasonable valuations to support future growth.
Capital Expenditures
- Option Care Health reported capital expenditures of approximately -$38 million in 2020, -$36 million in 2021, -$26 million in 2022, -$35 million in 2023, and -$42 million in 2024.
- Capital expenditures have consistently resulted in cash outflows due to ongoing capital investments and acquisitions.
- The company significantly expanded its infusion suite capacity from 43 in 2022 to 84 in 2023, increasing total infusion seats to over 660, with the aim of providing more patient locations and reducing costs for payors.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to OPCH. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.1% | 21.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.4% | -9.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 17.0% | 17.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.1% | 3.1% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Option Care Health
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 54.99 |
| Mkt Cap | 159.0 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.4% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | 9.4% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 12.1% |
| Op Mgn 3Y Avg | 11.9% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 14.6% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 11.6% |
| FCF/Rev 3Y Avg | 12.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 159.0 |
| P/S | 2.7 |
| P/EBIT | 21.1 |
| P/E | 33.0 |
| P/CFO | 20.7 |
| Total Yield | 4.5% |
| Dividend Yield | 2.1% |
| FCF Yield 3Y Avg | 5.7% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Price Behavior
| Market Price | $32.19 | |
| Market Cap ($ Bil) | 5.2 | |
| First Trading Date | 08/15/1996 | |
| Distance from 52W High | -8.6% | |
| 50 Days | 200 Days | |
| DMA Price | $29.77 | $30.43 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 8.1% | 5.8% |
| 3M | 1YR | |
| Volatility | 31.2% | 33.3% |
| Downside Capture | 23.36 | 46.84 |
| Upside Capture | 95.27 | 73.66 |
| Correlation (SPY) | 21.6% | 19.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.58 | 0.68 | 0.80 | 0.84 | 0.36 | 0.62 |
| Up Beta | 1.20 | 0.43 | 0.63 | 0.90 | 0.12 | 0.35 |
| Down Beta | -1.21 | -0.08 | -0.12 | 0.15 | 0.23 | 0.46 |
| Up Capture | 216% | 145% | 133% | 78% | 69% | 53% |
| Bmk +ve Days | 13 | 26 | 39 | 74 | 142 | 427 |
| Stock +ve Days | 13 | 22 | 32 | 56 | 129 | 377 |
| Down Capture | -14% | 82% | 122% | 138% | 70% | 99% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 7 | 20 | 31 | 68 | 117 | 369 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of OPCH With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| OPCH | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 40.4% | 13.8% | 16.7% | 65.4% | 7.5% | 4.2% | -7.3% |
| Annualized Volatility | 33.2% | 17.2% | 19.4% | 19.8% | 15.3% | 17.0% | 34.9% |
| Sharpe Ratio | 1.06 | 0.59 | 0.67 | 2.43 | 0.27 | 0.08 | -0.06 |
| Correlation With Other Assets | 34.0% | 19.7% | -6.9% | -9.1% | 31.6% | -2.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of OPCH With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| OPCH | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 16.5% | 8.4% | 14.8% | 17.7% | 11.2% | 5.1% | 30.2% |
| Annualized Volatility | 236.4% | 14.5% | 17.1% | 15.6% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | 0.86 | 0.40 | 0.70 | 0.91 | 0.48 | 0.18 | 0.57 |
| Correlation With Other Assets | 3.1% | 2.1% | -2.9% | -2.9% | -0.7% | 10.6% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of OPCH With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| OPCH | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 17.8% | 10.1% | 15.0% | 14.6% | 6.9% | 5.4% | 69.0% |
| Annualized Volatility | 174.7% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.70 | 0.50 | 0.72 | 0.82 | 0.31 | 0.23 | 0.89 |
| Correlation With Other Assets | 8.7% | 8.3% | -2.3% | 1.2% | 5.7% | 8.0% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/30/2025 | -8.6% | -5.5% | 7.9% |
| 7/30/2025 | 1.7% | -6.7% | -5.1% |
| 4/29/2025 | -6.9% | -0.5% | -3.7% |
| 1/13/2025 | 15.5% | 21.6% | 31.5% |
| 10/30/2024 | -22.8% | -26.8% | -22.1% |
| 7/31/2024 | -5.3% | -5.0% | 0.3% |
| 2/22/2024 | -2.4% | -5.2% | -2.9% |
| 10/25/2023 | -15.5% | -15.6% | -8.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 6 | 8 |
| # Negative | 9 | 11 | 9 |
| Median Positive | 8.2% | 10.8% | 7.6% |
| Median Negative | -6.9% | -5.5% | -8.2% |
| Max Positive | 147.9% | 157.3% | 169.6% |
| Max Negative | -22.8% | -26.8% | -22.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 10/30/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 07/30/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 04/29/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 02/26/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 10/30/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 07/31/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 04/23/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 02/22/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 10/25/2023 | 10-Q (09/30/2023) |
| 06/30/2023 | 07/27/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/04/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 02/23/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 10/27/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 07/27/2022 | 10-Q (06/30/2022) |
| 03/31/2022 | 04/28/2022 | 10-Q (03/31/2022) |
| 12/31/2021 | 02/23/2022 | 10-K (12/31/2021) |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.